Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, 56-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Utilizing Patient-Reported and Radiographic Outcomes to Evaluate the Efficacy and Safety of a Single Injection of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

Next Previous
Trial Profile

A Phase 3, 56-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Utilizing Patient-Reported and Radiographic Outcomes to Evaluate the Efficacy and Safety of a Single Injection of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lorecivivint (Primary)
  • Indications Osteoarthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms STRIDES X-ray
  • Sponsors Biosplice Therapeutics

Most Recent Events

  • 03 Jun 2023 Pooled analysis of two phase 2 trails (NCT02536833, NCT03122860) and two Phase 3 trials (NCT04385303, NCT03928184) presented at the 24th Annual Congress of the European League Against Rheumatism.
  • 14 Nov 2022 Post hoc pooled results presented at the ACR Convergence 2022.
  • 14 Nov 2022 Results assessing the safety and efficacy of Lorecivivint presented at the ACR Convergence 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top